Calendar
event
Ex dividend date
08 May 2019
event_available
Last Dividend Payment
01 Jan 1970
About Biotest Aktiengesellschaft
Ticker
info
BIO
Trading on
info
XETRA
ISIN
info
DE0005227201
Industry
info
-
Sector
info
-
CEO
info
Dr. Jorg Schuttrumpf
Headquarters
info
Landsteinerstrasse 5, Dreieich, undefined, Germany, 63303
Employees
info
2,495
Website
info
biotest.com
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immunoprophylaxis of hepatitis B in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and Yimmugo for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, including neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B immunoglobulins. In addition, it provides Albiomin and Biseco to restore and maintain circulating blood volume; Cofact for deficiency of coagulation factors; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. Biotest Aktiengesellschaft is a subsidiary of Grifols Biotest Holdings GmbH.
Metrics
BasicAdvanced
Market cap
info
€1.4B
P/E ratio
info
-
EPS
info
-€0.63
Dividend Yield
info
0.09%
Beta
info
0.09
Forward P/E ratio
info
526.32
EBIDTA
info
€46.8M
Ex dividend date
info
2019-05-08
Price & volume
Market cap
info
€1.4B
Average daily volume
info
-
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
€0.04
Dividend yield
info
0.09%
Forward dividend per share
info
€0.00
Forward dividend yield
info
0.10%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
526.32
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
2.2
Price to book
info
3.28
Earnings
EPS
info
-€0.63
EPS estimate (current quarter)
info
€0.00
EPS estimate (next quarter)
info
€0.00
EBITDA
info
€46.8M
Revenues (TTM)
info
€635M
Revenues per share (TTM)
info
€16.15
Technicals
Beta
info
0.09
52-week High
info
€43.20
52-week Low
info
€40.20
50-day moving average
info
€42.54
200-day moving average
info
€41.71
Short ratio
info
0
Short %
info
0.00%
Management effectiveness
ROE (TTM)
info
-4.72%
ROA (TTM)
info
0.52%
Profit margin
info
-3.86%
Gross profit margin
info
€147M
Operating margin
info
-17.71%
Growth
Quarterly earnings growth (YoY)
info
-56.40%
Quarterly revenue growth (YoY)
info
-42.30%
Share stats
Outstanding Shares
info
19.8M
Float
info
20M
Insiders %
info
-
Institutions %
info
0.07%
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
€0.25
-
-
Q2 • 24Beat
-€0.24
-
-
Q3 • 24Beat
-€0.09
-
-
Q4 • 24Beat
-€0.54
-
-
Q1 • 25Beat
-
-
-
Q2 • 25Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
€204M
€-3.5M
-1.72%
Q4 • 24
€124M
€-21.4M
-17.23%
Q1 • 25
-38.97%
511.43%
901.82%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
€1.43B
€903M
62.99%
Q4 • 24
€1.42B
€907M
64.02%
Q1 • 25
-1.22%
0.40%
1.64%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
€37.5M
€-4.4M
€50.1M
€8.8M
Q4 • 24
€-58.1M
€-1.1M
-
€-58.1M
Q1 • 25
-254.93%
-75.00%
NaN%
-760.23%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Biotest Aktiengesellschaft share?
Collapse

Biotest Aktiengesellschaft shares are currently traded for undefined per share.

How many shares does Biotest Aktiengesellschaft have?
Collapse

Biotest Aktiengesellschaft currently has 19.8M shares.

Does Biotest Aktiengesellschaft pay dividends?
Collapse

Yes, Biotest Aktiengesellschaft does pay dividends.

What is Biotest Aktiengesellschaft 52 week high?
Collapse

Biotest Aktiengesellschaft 52 week high is €43.20.

What is Biotest Aktiengesellschaft 52 week low?
Collapse

Biotest Aktiengesellschaft 52 week low is €40.20.

What is the 200-day moving average of Biotest Aktiengesellschaft?
Collapse

Biotest Aktiengesellschaft 200-day moving average is €41.71.

Who is Biotest Aktiengesellschaft CEO?
Collapse

The CEO of Biotest Aktiengesellschaft is Dr. Jorg Schuttrumpf.

How many employees Biotest Aktiengesellschaft has?
Collapse

Biotest Aktiengesellschaft has 2,495 employees.

What is the market cap of Biotest Aktiengesellschaft?
Collapse

The market cap of Biotest Aktiengesellschaft is €1.4B.

What is the P/E of Biotest Aktiengesellschaft?
Collapse

The current P/E of Biotest Aktiengesellschaft is null.

What is the EPS of Biotest Aktiengesellschaft?
Collapse

The EPS of Biotest Aktiengesellschaft is -€0.63.

What is the PEG Ratio of Biotest Aktiengesellschaft?
Collapse

The PEG Ratio of Biotest Aktiengesellschaft is 0.